Medical imaging solutions provider Median Technologies and technology giant Microsoft have signed a collaborative agreement to develop new cancer detection, diagnosis and monitoring methods utilizing big data analytics.
Under the joint global initiative, Median will install its imaging biomarker phenotyping system (IBIOPSY) on the Microsoft Azure cloud computing platform.
IBIOPSY will be able to process and analyze medical images on the Azure platform, and extract disease biomarkers in real time to diagnose and treat cancer.
Medical facilities and physicians in the US, Europe, and Asia will get accessibility to IBIOPSY system in order to address the image processing and data analytics requirements.
Median and Microsoft will work together to help medical centers take advantage of the Azure capabilities.
The companies will also develop novel predictive analytics methods depending on machine learning and encryption capabilities that will be available on Azure.
Median Technologies CEO Fredrik Brag said: "Extracting biomarkers of disease from medical images is at the core of the Precision Medicine effort.
"Big Data computing and analytics will allow efficient processing and analysis of imaging biomarkers which is essential for early detection of cancer and monitoring of new targeted cancer treatments."
Microsoft France chief technology and security officer Bernard Ourghanlian said: "By taking advantage of the powerful Microsoft Azure cloud platform, IBIOPSY™ will provide faster imaging and health data analysis and will accelerate the discovery and delivery of new biomarkers for cancer diagnosis and treatment monitoring."
Based in Sophia-Antipolis of France, Median provides medical imaging software and services for oncology clinical trials, cancer screening and clinical practice.
Image: Microsoft European HQ – Paris. France. Photo: courtesy of Elekes Andor.